制药

Jazz Pharmaceuticals: A Fair Price for an Unfinished Second Act

Jazz Pharmaceuticals is an Irish-domiciled specialty biopharma whose durable Xywav/Xyrem sleep franchise has funded a pivot into rare epilepsy (Epidiolex) and oncology (zanidatamab, Modeyso, Zepzelca). 2025 revenue reached $4.27 billion with $1.36 billion of operating cash flow, and Q1 2026 revenue grew 19% to $1.069 billion as the market now turns on zanidatamab's August 25, 2026 FDA decision in first-line gastric cancer and on how long Xywav can outrun Lumryz and generic competition. Rating Hold: at $238.05 the stock already prices durable Xywav defense and a timely zanidatamab step-up, leaving no meaningful margin of safety.

BeOne Medicines: A Real Oncology Winner, Already Priced For More

BeOne Medicines, formerly BeiGene, is a global oncology biopharma whose economics now turn on one drug, BRUKINSA, the BTK inhibitor that outsold AstraZeneca's Calquence and AbbVie's Imbruvica in 2025 with $3.93 billion of revenue as the company crossed into sustained GAAP profitability. Full-year 2025 revenue reached $5.34 billion with $1.13 billion of operating cash flow, and first-quarter 2026 extended the trend with an 89% gross margin and raised full-year guidance, even as BRUKINSA still supplies roughly three-quarters of product revenue. Rating Hold: commercial execution and BTK leadership are real and durable, but at $303.96 the stock already prices continued BRUKINSA strength and a successful platform broadening that remains unproven, leaving no meaningful margin of safety.

Legend Biotech: CARVYKTI Is a Real Franchise, Self-Funding Is Still Unproven

Legend Biotech is a commercial-stage cell-therapy company whose economics are dominated by CARVYKTI, the BCMA CAR-T it shares equally with Johnson & Johnson outside Greater China while bearing and retaining 70% in Greater China. Collaboration revenue reached 944.8 million USD in 2025 and quarterly CARVYKTI trade sales hit 597 million USD in Q1 2026, up 62% year over year, yet the same quarter still showed a 54.3 million USD net loss and June 2026 brought a follow-on offering of about 226 million USD gross. Rating Hold: CARVYKTI is a real franchise, but the current price does not pay generously for single-asset concentration, shared economics, and continuing dilution risk, and new capital only gets attractive at 22 to 24 USD.

UCB SA: A Specialty-Biopharma Growth Platform That Has Already Re-Rated

UCB is a Belgian specialty biopharma in immunology and neurology, and BIMZELX is now its largest product at €2.227 billion of 2025 net sales. FY2025 revenue rose 26% to €7.741 billion, adjusted EBITDA jumped to €2.636 billion, and the balance sheet swung from €1.454 billion of net debt to roughly net cash; yet at €258.50, about 24x forward earnings, the price already embeds much of the BIMZELX and portfolio ramp. Rating Hold: a genuinely stronger company at a price that leaves essentially no margin of safety for fresh capital.

Sanofi SA: A Pure-Play in Transition, Still Proving Life After Dupixent

Sanofi is a French pure-play biopharma built around immunology, vaccines, and rare disease after ceding control of Opella. Dupixent alone reached 15.714 billion EUR of 2025 sales, about 36% of group revenue, and still grew 30.8% in Q1 2026, yet the market withholds a growth multiple until a post-Dupixent bridge is proven ahead of the roughly 2031 patent cliff. Rating Hold: a cleaner, cash-generative business at a cheapish multiple with 8.089 billion EUR of 2025 free cash flow, but no wide margin of safety on the hard part of the story.

GSK plc: Rebuilt Biopharma, Racing the Patent Cliff

GSK plc is a UK biopharma rebuilt around vaccines and specialty medicines after the 2022 Haleon demerger, with 2025 sales of £32.7bn anchored by Shingrix and the ViiV HIV franchise. Specialty medicines now drive growth (£13.5bn, +14% CER in Q1 2026) and core operating profit rose 11% to £9.8bn, yet the whole story hinges on replacing the dolutegravir HIV cliff in 2028–2030 before it arrives. Rating Hold: a genuinely higher-quality franchise at roughly 11.6x core earnings, but the price already assumes much of the patent-cliff bridge, leaving little margin of safety.

Hengrui Pharmaceuticals: A Fortress Innovation Platform, But RMB 50 Already Pays for the Upgrade

Hengrui Pharmaceuticals is China's largest listed innovative-drug platform, still earning mainly from domestic drug sales while its valuation increasingly rests on converting self-funded R&D into commercial franchises and recurring overseas licensing income. 2025 revenue reached RMB 31.63 billion with net profit of RMB 7.71 billion and a fortress balance sheet holding RMB 40.16 billion of cash, yet at RMB 50.04 (about 41x trailing earnings) the price sits above the conservative fair value and leaves no margin of safety. Rating Hold: a rare high-quality China pharma platform already priced for an innovation-monetization upgrade it has not yet fully earned.

RemeGen: Two Self-Developed Drug Franchises and an Export Licensing Engine, With the A-Share Already Pricing a Cleaner Future Than the Filings Justify

RemeGen is a commercializing China innovative-biopharma with two self-developed franchises — telitacicept in autoimmune disease and disitamab vedotin in ADC oncology — plus an ex-China licensing engine (Vor Bio, Santen, AbbVie) that has become part of the business model. 2025 product sales reached CNY 2.31bn (up 35.8%) and reported profit turned positive at CNY 709.7m, but operating cash flow was only CNY 52.3m (about 0.07x conversion), Q1 2026 profit after non-recurring items stayed negative, and the A-share trades at roughly a 96.5% premium to the H-share — above even the optimistic per-share value. Rating Avoid: a good company at the wrong price on the Shanghai line, where an entry needs both a lower A-share price (CNY 36-40) and proof that recurring earnings quality has caught up to the approvals.

Kelun-Biotech: A Commercializing China ADC Franchise Priced for Much of Its sac-TMT and MSD Global Success

Kelun-Biotech is a commercial-stage China ADC developer whose equity value is dominated by its sac-TMT (TROP2) franchise in Greater China plus ex-China royalty economics from MSD. In 2025 product sales inflected to RMB542.7m within RMB2.06bn total revenue and the balance sheet held RMB4.56bn cash with no borrowings, yet the company still posted a RMB382.0m net loss as nearly all equity value concentrates in one molecule. Rating Hold: a real ADC franchise is forming, but at HK$419 the stock already prices in much of the sac-TMT China plus MSD global success path and offers no margin of safety.

Akeso, Inc.: A Commercial-Stage Antibody Innovator Still Priced on Ivonescimab's Global Option Value

Akeso is a commercial-stage Chinese antibody innovator with seven marketed products and record 2025 commercial sales of RMB3.03 billion, anchored by cadonilimab and ivonescimab. Yet the stock trades as a referendum on one molecule: whether ivonescimab's strong China data (a HARMONi-6 overall-survival win, HR 0.66) can survive global regulators, while 2025 operating cash flow stayed negative at RMB947.6 million and the shares fetch about 22x trailing sales. Rating Hold: rare science and a real China franchise, but the price still pre-pays too much of ivonescimab's ex-China upside; the ideal buy zone is HK$58-64.

阿斯利康 AstraZeneca 深度研究

阿斯利康是以肿瘤与罕见病为核心、靠研发与全球商业化变现的创新药巨头。2025 年收入 587.39 亿美元，增长重心向肿瘤（同比 +20%）与罕见病（+19%）集中、对冲 CVRM 老药承压，多平台结构比单引擎同业更均衡。研报评级持有：现价 178.75 美元对保守内在价值仍有溢价、安全边际不明显，高质量但已进入兑现压力期。

诺华(NVS) 横纵研报

诺华是瑞士巴塞尔总部的全球十大创新药企之一，2023 年 10 月剥离仿制药/生物类似药子公司 Sandoz 后转型为"纯创新药"pureplay，治疗管线覆盖心血管（Entresto）、肿瘤（Pluvicto/Kisqali）、免疫（Cosentyx）、神经（Kesimpta）、罕见病（Leqvio）；2025 财年营收 ~566 亿美元、营业利润率 30%、自由现金流 ~150 亿美元、股息连涨 28 年；当前最大挑战是 Entresto 心衰药 2025 年第四季度美国进入仿制药竞争。

天辰生物-B 横纵分析研究

中国 18A 创新药新股，核心抗 IgE 抗体 LP-003 临近 BLA；截至 2026-06-03 尚未上市交易，招股价 96.06 港元已计入不少成功预期、较保守内在价值 67.4 港元明显溢价。零收入零利润、价值高度集中 LP-003。理想买入 ≤54 港元。

Viatris 投资深度研究报告

全球仿制药与成熟品牌药平台，现金流稳但护城河弱、资产质量一般。当前约 16.26 美元落在合理价值下部，安全边际不足，给观察，理想买入 11-13.5 美元。

Moderna 长期企业所有者视角研究

mRNA 平台生物制药公司，新冠疫苗起家，现金尚可但已转入烧钱等新品接棒的转型期；价值高度依赖少数审批与肿瘤三期，安全边际不足，评级观察。

Incyte 横纵分析研究

现金流够强但后 Jakafi 时代仍待证明,Jakafi 2028 年专利压力是真问题,合理买入区间 80-88 美元,当前 97 美元缺乏安全边际。

Zoetis 长期企业所有者视角价值分析

全球动物保健龙头，约 300 条产品线、2025 收入 94.67 亿、毛利率 71.8%、ROIC ~29%、FCF 22.83 亿；估值 70-80 / 100-120 / 150-180 vs 现价 80.23（forward P/E 11.6x），理想买入 65-75，2026 美国伴侣动物 -11% 是关键裂缝。

Johnson & Johnson 深度价值分析：好公司不便宜

JNJ 是一家可理解、护城河深、自由现金流稳定的医疗龙头，但 234 美元的价格已接近模型乐观情景上沿、安全边际不足；现金回报率 3.4% 低于 10 年美债 4.57%，新买家更应等待。

Eli Lilly 深度价值研究：好公司的过高价格

tirzepatide 平台让 Lilly 站上代谢赛道顶端，但 732 美元的市值已经提前为下一代管线和产能扩张付钱；DCF 中性内在价值仅 560-680 美元，安全边际不足，更适合等价格回调。

Merck 长期企业所有者视角研究

全球创新药龙头，Keytruda 占 2025 年收入 49%；当前价 122.41 美元 FCF 收益率仅 4.1%，低于 10 年期美债，对 2028-2029 年专利悬崖安全边际不足。

Pfizer 长期企业所有者视角投资研究

大型制药修复期,2025 收入 625.8 亿 / OCF 117 亿,剔除 COVID 后核心盘 +6%,股息覆盖宽,Vyndaqel 专利和解延至 2031,Seagen/Metsera 资本配置仍待证;当前 25.85 美元接近中性内在价值,合理买入区 18–21 美元。

Biogen 价值投资深度评估

神经科学生物制药公司，MS 老药受仿制冲击、LEQEMBI/SKYCLARYS 新药接棒中；现价 193.76 美元约 13.6x Owner Earnings，安全边际不充裕，理想买入 130-150 美元。

Bristol-Myers Squibb 价值投资深度研究

全球大型制药龙头，2025 营收 481.9 亿、FCF 128.5 亿、股息率 4.24%；当前 59.46 美元，理想买入 45–52 美元，专利悬崖叠加管线接棒不确定，安全边际不够厚。

Vertex Pharmaceuticals 长期所有者视角研究

CF franchise 护城河深、毛利率 86.2%、净现金 130 亿美元；但 98.5% 产品收入仍来自 CF，去 CF 化处于早期；当前 P/E 25.8x、约 35 倍保守 owner earnings，价格已计入新管线兑现预期，安全边际不充足。

Regeneron Pharmaceuticals 长期企业所有者视角价值分析

一体化创新生物药龙头，Dupixent 分成 + EYLEA HD/Libtayo 接棒，2025 净利 45 亿美元、净现金 158 亿美元；当前 642.59 美元 / 15.7 倍 PE 落在「可以持有」区间但安全边际不厚，理想买入 450–550 美元，评级观察。

Insmed 深度价值投资研究报告

好公司、贵价格。ARIKAYCE 与 BRINSUPRI 是稀缺呼吸专科资产，但当前约 109.5 美元已计入多重成功，owner earnings 仍为负、安全边际不足，合理买入区间 55–70 美元。

Gilead Sciences 深度价值投资研究

HIV 护城河真实、现金流扎实的成熟药企，2025 年收入 294.43 亿美元、自由现金流约 94.56 亿美元。当前约 130.50 美元股价已为并购与新管线接棒预先付费，安全边际不明显。保守内在价值 70-90、合理 100-125、乐观 145-165 美元。

AbbVie 长期企业所有者视角深度研究

已走出 Humira 专利悬崖，Skyrizi/Rinvoq 双核接力（2025 年合计约占收入 42%），现金流强、分红扎实；当前 212.30 美元安全边际不足、账面负权益，评级观察，理想买入区 155-180 美元。

Alnylam Pharmaceuticals 深度价值投资分析

RNAi 创新药公司，2025 年首次全年盈利、AMVUTTRA 驱动放量；但收入高度集中、SBC 与融资结构复杂，约 299 美元缺乏安全边际，理想买入 200-240 美元。

Amgen Inc. 深度价值投资分析

高质量但当前不便宜的成熟生物制药资产；专利悬崖、医保压价与 Horizon 并购后重资产负债表下，约 331 美元缺乏安全边际，理想买入 240-280 美元。

Novo Nordisk 长期所有者视角研究

高质量制药生意：ROIC 39-88% 高位、GLP-1 重注射型份额 55%；但面 Lilly 口服 GLP-1 上市 + 美国价格政策 + semaglutide 部分国际市场失独占，Owner Earnings 口径看 20-23x，静态 PE 12.5x 的便宜是假象。